World's First HPV Genotyping & Normalized Quantification Assay

Despite decades of progress, cervical cancer remains a leading cause of cancer-related deaths among women globally. Traditional screening methods struggle to balance underscreening gaps and overtreatment risks—a dilemma now addressed by genotype-specific viral load quantification.

Cervical cancer screening is evolving from the qualitative "positive/negative" paradigm to a precision-driven era of genotyping paired with standardized viral load quantification—a dual-strategy approach that redefines clinical decision-making.

A globally recognized leader in HPV detection and cervical cancer prevention

-Vice President of Fujian Maternal and Child Health Hospital

-Director of Fujian Provincial Clinical Research Center for Gynecological Oncology

As a core member of the WHO Cervical Cancer Guideline Revision Panel, Prof. Sun’s work aligns with WHO 90-70-90 elimination targets and has been recognized through keynote speeches at IPVC for four consecutive years.

Honored as an Outstanding Contribution Expert and recipient of the Fujian Natural Science Award, Sun bridges AI innovation with clinical practice, driving transformative solutions in cervical cancer prevention worldwide.

World's First HPV Genotyping & Normalized Quantification Assay: Clinical Breakthroughs and Evidence-Based Impact

Next-Gen Cervical Screening: Integrating Genotyping with Viral Load

Global Guidelines Insight

Cutting-Edge Technology

Evidence-Driven Validation

Critical Clinical Value

About the Speaker

Prof. Pengming Sun, MD, PhD

Agenda Highlights